AstraZeneca has announced results from the ADAURA phase 3 trial showing Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo. This OS benefit was seen in patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection.
These results were presented during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, Republic of Korea (Abstract PL03.01). The data was also simultaneously published in the Journal of Thoracic Oncology.
At eight years of follow-up, results showed that Tagrisso continued to show an OS benefit, reducing the risk of death compared to placebo by 47% in the primary population. In the overall trial population, Tagrisso reduced the risk of death compared to placebo by 48%.
An estimated 74% of patients treated with Tagrisso were alive at eight years versus 58% of those treated with placebo in the primary population. In the overall trial population, an estimated 79% of patients treated with Tagrisso were alive at eight years versus 64% of those treated with placebo.
Lung cancer is the leading cause of cancer death globally, accounting for almost one in five (19%) cancer deaths. Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC. Approximately 75% of NSCLC patients are diagnosed with advanced disease while approximately 25-30% present with resectable disease at diagnosis. Early-stage lung cancer diagnoses are often only made when the cancer is found on imaging for an unrelated condition.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “ADAURA continues to set new benchmarks in early-stage EGFR-mutated lung cancer, with nearly 80% of patients treated with adjuvant Tagrisso alive at eight years. These results underscore the importance of treating early and reinforce Tagrisso as the adjuvant standard of care and backbone therapy across stages of the disease.”